AXSM - Axsome Therapeutics Stock Price, News & Analysis

$4.90 0.25 (5.38 %)
(As of 11/24/2017 04:00 PM ET)
Previous Close$4.65
Today's Range$4.75 - $4.90
52-Week Range$3.53 - $7.40
Volume119,500 shs
Average Volume177,381 shs
Market Capitalization$115.99 million
P/E RatioN/A
Dividend YieldN/A
Beta0.95

About Axsome Therapeutics (NASDAQ:AXSM)

Axsome Therapeutics logoAxsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AXSM
CUSIPN/A

Debt

Debt-to-Equity Ratio0.44%
Current Ratio3.86%
Quick Ratio3.86%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.71 per share
Price / Book6.90

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($1.36)
Net Income$-27,200,000.00
Net MarginsN/A
Return on Equity-127.58%
Return on Assets-73.83%

Miscellaneous

Employees22
Outstanding Shares23,670,000

Frequently Asked Questions for Axsome Therapeutics (NASDAQ:AXSM)

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) released its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.30) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.31) by $0.01. View Axsome Therapeutics' Earnings History.

Where is Axsome Therapeutics' stock going? Where will Axsome Therapeutics' stock price be in 2017?

4 brokers have issued 1 year price objectives for Axsome Therapeutics' stock. Their predictions range from $13.00 to $31.00. On average, they expect Axsome Therapeutics' stock price to reach $19.50 in the next year. View Analyst Ratings for Axsome Therapeutics.

What are Wall Street analysts saying about Axsome Therapeutics stock?

Here are some recent quotes from research analysts about Axsome Therapeutics stock:

  • 1. According to Zacks Investment Research, "Axsome Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing novel therapies for the management of pain and other central nervous system disorders. Its product candidate portfolio consists of AXS-02 and AXS-05 which are in clinical trial stage. Axsome Therapeutics, Inc. is based in New York. " (11/15/2017)
  • 2. Aegis analysts commented, "We believe Ms. Potter’s prior experience adds value to the Board of Directors for Axsome. Her career in healthcare spans more than 30 years with multiple leadership positions at several large pharmaceutical companies. As Axsome looks to report multiple phase III interim analysis and topline readouts over the next 24 months, her experience in the commercialization process should go a long way for management. Myrtle Potter – Prior experience. After starting her career with Procter and Gamble Patient Care Products, Ms. Potter went on to spend 14 years of her early career at Merck & Co. While holding positions of increasing responsibility at Merck, she started Astra Merck, a joint venture entity that later became AstraZeneca, and served as Vice President of Merck’s US pharmaceutical business unit with about $800 mil revenue. Ms. Potter also served as President of Bristol-Myers Squibb’s US Cardiovascular and Metabolic Business – a 3,500 person business segment with $3.5 billion annual revenue – for 4 years. From 2000 to 2005 she was President, Commercial Operations and Chief Operating Officer at Genentech. While at Genentech, Ms. Potter led the commercialization of a long list of products: Herceptin, Tarceva, Xolair, Avastin, Rituxan, Nutropin, Activase, and TNkase." (6/20/2017)

Who are some of Axsome Therapeutics' key competitors?

Who are Axsome Therapeutics' key executives?

Axsome Therapeutics' management team includes the folowing people:

  • Herriot Tabuteau M.D., Chairman of the Board, Chief Executive Officer (Age 47)
  • John Golubieski, Chief Financial Officer (Age 52)
  • Constance Ames, Vice President - Finance (Age 29)
  • Mark Jacobson, Senior Director - Operations (Age 32)
  • Randall E. Kaye M.D., Chief Medical Officer (Age 53)
  • Robert Niecestro Ph.D., Head of Regulatory (Age 64)
  • Mark Coleman M.D., Independent Director (Age 47)
  • Roger A. Jeffs Ph.D., Independent Director (Age 55)
  • Myrtle S. Potter, Independent Director (Age 58)
  • Mark Saad, Independent Director

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

Who owns Axsome Therapeutics stock?

Axsome Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (6.18%). View Institutional Ownership Trends for Axsome Therapeutics.

Who bought Axsome Therapeutics stock? Who is buying Axsome Therapeutics stock?

Axsome Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co.. View Insider Buying and Selling for Axsome Therapeutics.

How do I buy Axsome Therapeutics stock?

Shares of Axsome Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Axsome Therapeutics' stock price today?

One share of Axsome Therapeutics stock can currently be purchased for approximately $4.90.

How big of a company is Axsome Therapeutics?

Axsome Therapeutics has a market capitalization of $115.99 million. The company earns $-27,200,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Axsome Therapeutics employs 22 workers across the globe.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 25 BROADWAY 9TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-332-3241.


MarketBeat Community Rating for Axsome Therapeutics (AXSM)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  116 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  192
MarketBeat's community ratings are surveys of what our community members think about Axsome Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Axsome Therapeutics (NASDAQ:AXSM)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.572.573.00
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.25$17.38$19.60$18.80
Price Target Upside: 255.67% upside247.50% upside243.86% upside358.54% upside

Consensus Price Target History for Axsome Therapeutics (NASDAQ:AXSM)

Price Target History for Axsome Therapeutics (NASDAQ:AXSM)

Analysts' Ratings History for Axsome Therapeutics (NASDAQ:AXSM)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/26/2017Ladenburg Thalmann Financial ServicesReiterated RatingBuy$28.00 -> $31.00HighView Rating Details
6/20/2017AegisReiterated RatingBuy$20.00HighView Rating Details
5/19/2017BTIG ResearchInitiated CoverageBuy$14.00HighView Rating Details
3/8/2017Cantor FitzgeraldSet Price TargetBuy$13.00LowView Rating Details
10/3/2016Brean CapitalInitiated CoverageBuy$20.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Axsome Therapeutics (NASDAQ:AXSM)

Earnings by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Earnings History by Quarter for Axsome Therapeutics (NASDAQ AXSM)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($0.31)($0.30)ViewN/AView Earnings Details
5/9/20173/31/2017($0.40)($0.41)ViewN/AView Earnings Details
11/14/2016Q3($0.39)($0.38)ViewN/AView Earnings Details
8/9/2016Q2 2016($0.39)($0.36)ViewN/AView Earnings Details
5/11/2016Q116($0.28)($0.31)ViewN/AView Earnings Details
3/24/2016Q416($0.22)($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Axsome Therapeutics (NASDAQ:AXSM)
Current Year EPS Consensus Estimate: $-1.31 EPS
Next Year EPS Consensus Estimate: $-0.18 EPS

Dividends

Dividend History for Axsome Therapeutics (NASDAQ:AXSM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Axsome Therapeutics (NASDAQ AXSM)

Insider Ownership Percentage: 35.20%
Institutional Ownership Percentage: 25.79%
Insider Trades by Quarter for Axsome Therapeutics (NASDAQ:AXSM)
Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Insider Trades by Quarter for Axsome Therapeutics (NASDAQ AXSM)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/23/2015Randall KayeInsiderBuy1,000$9.03$9,030.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Axsome Therapeutics (NASDAQ AXSM)

Source:
DateHeadline
Axsome Therapeutics, Inc. (AXSM) Receives Consensus Recommendation of "Buy" from BrokeragesAxsome Therapeutics, Inc. (AXSM) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 20 at 3:58 AM
Axsome Therapeutics, Inc. (AXSM) Upgraded to "Buy" by Zacks Investment ResearchAxsome Therapeutics, Inc. (AXSM) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - November 15 at 5:06 PM
Axsome Therapeutics Reports Third Quarter 2017 Financial ResultsAxsome Therapeutics Reports Third Quarter 2017 Financial Results
www.thestreet.com - November 8 at 6:42 PM
Axsome Therapeutics, Inc. (AXSM) Scheduled to Post Quarterly Earnings on MondayAxsome Therapeutics, Inc. (AXSM) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - November 6 at 5:22 AM
Axsome Therapeutics (AXSM) and Kite Pharma (KITE) Critical SurveyAxsome Therapeutics (AXSM) and Kite Pharma (KITE) Critical Survey
www.americanbankingnews.com - October 31 at 7:16 PM
Axsome Therapeutics, Inc. (AXSM) Receives Average Rating of "Buy" from AnalystsAxsome Therapeutics, Inc. (AXSM) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - October 26 at 3:32 AM
Axsome Therapeutics, Inc. (AXSM) Lowered to "Hold" at Zacks Investment ResearchAxsome Therapeutics, Inc. (AXSM) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 17 at 5:16 PM
Axsome Therapeutics to Present at Upcoming Investor ConferencesAxsome Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - October 5 at 2:17 PM
Reviewing Insmed (INSM) and Axsome Therapeutics (AXSM)Reviewing Insmed (INSM) and Axsome Therapeutics (AXSM)
www.americanbankingnews.com - October 5 at 6:50 AM
Axsome Therapeutics Inc (AXSM) Given Average Rating of "Buy" by BrokeragesAxsome Therapeutics Inc (AXSM) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 1 at 2:50 AM
Axsome Therapeutics (AXSM) Reports CREATE-1 Interim Analysis Expected Year-End 2017Axsome Therapeutics (AXSM) Reports CREATE-1 Interim Analysis Expected Year-End 2017
www.streetinsider.com - September 8 at 4:43 PM
Axsome reports 2Q lossAxsome reports 2Q loss
finance.yahoo.com - September 7 at 4:20 PM
Axsome Announces CREATE-1 Interim Analysis Expected Year-End 2017Axsome Announces CREATE-1 Interim Analysis Expected Year-End 2017
finance.yahoo.com - September 7 at 4:20 PM
Axsome Therapeutics, Inc. (AXSM) Given Consensus Rating of "Buy" by AnalystsAxsome Therapeutics, Inc. (AXSM) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - September 6 at 2:28 AM
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Recommendation of "Buy" from AnalystsAxsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 12 at 2:32 AM
Axsome Therapeutics, Inc. (AXSM) Posts Quarterly  Earnings Results, Beats Estimates By $0.01 EPSAxsome Therapeutics, Inc. (AXSM) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - August 10 at 3:42 PM
Axsome Therapeutics Reports Second Quarter 2017 Financial ResultsAxsome Therapeutics Reports Second Quarter 2017 Financial Results
globenewswire.com - August 9 at 4:27 PM
Axsome Therapeutics, Inc. (AXSM) to Release Quarterly Earnings on MondayAxsome Therapeutics, Inc. (AXSM) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - July 31 at 8:05 AM
Axsome Therapeutics (AXSM) Buy Rating Reaffirmed at Ladenburg Thalmann Financial ServicesAxsome Therapeutics' (AXSM) Buy Rating Reaffirmed at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - July 26 at 12:40 PM
Axsome Therapeutics Announces AXS-06 (MoSEIC™ Meloxicam and Esomeprazole) Meets Primary Endpoint in Phase 1 Clinical TrialAxsome Therapeutics Announces AXS-06 (MoSEIC™ Meloxicam and Esomeprazole) Meets Primary Endpoint in Phase 1 Clinical Trial
finance.yahoo.com - July 25 at 4:09 PM
Axsome Therapeutics, Inc. (AXSM) Given Average Rating of "Buy" by BrokeragesAxsome Therapeutics, Inc. (AXSM) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 18 at 1:53 PM
Axsome Therapeutics Initiates Phase 2/3 Trial of AXS-05 for Alzheimer’s Disease AgitationAxsome Therapeutics Initiates Phase 2/3 Trial of AXS-05 for Alzheimer’s Disease Agitation
finance.yahoo.com - July 17 at 4:37 PM
Axsome Therapeutics Appoints John Golubieski as Chief Financial OfficerAxsome Therapeutics Appoints John Golubieski as Chief Financial Officer
feeds.benzinga.com - July 6 at 7:38 AM
Axsome reports 1Q lossAxsome reports 1Q loss
marketbeat.com - May 9 at 9:56 AM
Axsome Therapeutics Reports First Quarter 2017 Financial ResultsAxsome Therapeutics Reports First Quarter 2017 Financial Results
globenewswire.com - May 9 at 9:05 AM
Axsome Therapeutics (AXSM) Receives FDA Fast Track Designation for AXS-05 for AD AgitationAxsome Therapeutics (AXSM) Receives FDA Fast Track Designation for AXS-05 for AD Agitation
www.streetinsider.com - May 8 at 3:40 PM
Axsome Therapeutics (AXSM) Announces 3.74M Share Pricing at $3.74Axsome Therapeutics (AXSM) Announces 3.74M Share Pricing at $3.74
www.streetinsider.com - March 21 at 9:11 PM
Axsome Therapeutics Announces Proposed Public Offering of Common StockAxsome Therapeutics Announces Proposed Public Offering of Common Stock
us.rd.yahoo.com - March 21 at 4:09 PM
Axsome Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business UpdateAxsome Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
us.rd.yahoo.com - March 8 at 1:50 AM
AXSOME THERAPEUTICS, INC. Files SEC form 10-K, Annual ReportAXSOME THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 8 at 1:50 AM
Axsome Therapeutics (AXSM) Granted FDA Fast Track Status for AXS-05Axsome Therapeutics (AXSM) Granted FDA Fast Track Status for AXS-05
www.streetinsider.com - February 16 at 8:41 AM
AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsAXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - February 14 at 8:20 PM
Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Treatment Resistant DepressionAxsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Treatment Resistant Depression
us.rd.yahoo.com - February 14 at 3:16 PM
7:05 am Axsome Therapeutics receives fast track designation from the FDA for AXS-05 for treatment resistant depression7:05 am Axsome Therapeutics receives fast track designation from the FDA for AXS-05 for treatment resistant depression
us.rd.yahoo.com - February 14 at 3:16 PM
Axsome Therapeutics (AXSM) IND for AXS-05 Phase 2/3 Trial in AD Cleared by FDAAxsome Therapeutics (AXSM) IND for AXS-05 Phase 2/3 Trial in AD Cleared by FDA
www.streetinsider.com - January 3 at 8:35 AM
AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct FinancAXSOME THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financ
biz.yahoo.com - November 10 at 9:49 PM
AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial StatAXSOME THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Stat
biz.yahoo.com - September 3 at 9:16 AM
Axsome Therapeutics Reports Second Quarter 2016 Financial ResultsAxsome Therapeutics Reports Second Quarter 2016 Financial Results
www.nasdaq.com - August 10 at 8:28 AM
AXSOME THERAPEUTICS, INC. Files SEC form 10-K/A, Annual ReportAXSOME THERAPEUTICS, INC. Files SEC form 10-K/A, Annual Report
biz.yahoo.com - August 9 at 4:49 PM
AXSOME THERAPEUTICS, INC. Files SEC form 10-K/A, Annual ReportAXSOME THERAPEUTICS, INC. Files SEC form 10-K/A, Annual Report
biz.yahoo.com - August 9 at 4:49 PM
AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsAXSOME THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - July 13 at 7:01 AM
AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Non-Reliance on Previous Financials, Audits or Interim ReviewAXSOME THERAPEUTICS, INC. Files SEC form 8-K, Non-Reliance on Previous Financials, Audits or Interim Review
biz.yahoo.com - July 12 at 4:41 PM
AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersAXSOME THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - June 10 at 4:08 PM
AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andAXSOME THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
biz.yahoo.com - May 11 at 5:20 PM
AXSOME THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly ReportAXSOME THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - May 11 at 4:16 PM
Axsome Therapeutics Receives Pre-IND Guidance From FDA For AXS-05 For Agitation In Patients With Alzheimers DiseaseAxsome Therapeutics Receives Pre-IND Guidance From FDA For AXS-05 For Agitation In Patients With Alzheimer's Disease
www.thestreet.com - April 20 at 9:56 AM
AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, FinancialAXSOME THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial
biz.yahoo.com - March 29 at 4:21 PM

Social Media

Financials

Chart

Axsome Therapeutics (NASDAQ AXSM) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.